{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T11:06:00Z","timestamp":1789729560582,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development and application of radiopharmaceuticals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Main body<\/jats:title>\n            <jats:p>This selection of highlights provides commentary on 24 different topics selected by each co-authoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Trends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field in many aspects.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s41181-025-00335-w","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T01:37:53Z","timestamp":1742953073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Highlight selection of radiochemistry and radiopharmacy developments by editorial board"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1348-0309","authenticated-orcid":false,"given":"S.","family":"Spreckelmeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Dasilva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Decristoforo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. H.","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Passchier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Carlucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Al","family":"Qahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Duatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. T.","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Engle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Denkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J. M. A.","family":"Hendrikx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Seimbille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M-R.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Perk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Caravan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Laverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Hoehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. R.","family":"Zeevaart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"335_CR1","first-page":"e17","volume":"50","author":"M Bahtouee","year":"2025","unstructured":"Bahtouee M, Jafari E, Khazaei M, Aram N, Amini A, Jokar N, Ahmadzadehfar H, Gholamrezanezhad A, Assadi M. Exploring the potential value of [68Ga]Ga-FAPI-46 PET\/CT for molecular assessment of fibroblast activation in interstitial lung disease: A Single-Center pilot study. Clin Nucl Med. 2025;50:e17\u201325.","journal-title":"Clin Nucl Med"},{"key":"335_CR2","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s00259-023-06462-3","volume":"51","author":"H Berglund","year":"2024","unstructured":"Berglund H, Salomonsson SL, Mohajershojai T, Gago FJF, Lane DP, Nestor M. p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts. Eur J Nucl Med Mol Imaging. 2024;51:768\u201378.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"335_CR3","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1080\/028418601750444141","volume":"40","author":"P Bernhardt","year":"2001","unstructured":"Bernhardt P, Forssell-Aronsson E, Jacobsson L, Skarnemark G. Low-energy electron emitters for targeted radiotherapy of small tumours. Acto Oncol. 2001;40:602\u20138.","journal-title":"Acto Oncol"},{"issue":"4","key":"335_CR4","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00259-021-05564-0","volume":"49","author":"F Borgna","year":"2022","unstructured":"Borgna F, Haller S, Monn\u00e9 Rodriguez JM, Ginj M, Grundler PV, Zeevaart JR, Koester U, Schibli R, van der Meulen NP, Mueller C. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022;49(4):1113\u201326.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"335_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41181-024-00264-0","volume":"9","author":"A Boschi","year":"2024","unstructured":"Boschi A, Urso L, Uccelli L, Martini P, Filippi L. 99mTc-labeled FAPI compounds for cancer and inflammation: from radiochemistry to the first clinical applications. EJNMMI Radiopharmacy Chem. 2024;9(1):36.","journal-title":"EJNMMI Radiopharmacy Chem"},{"issue":"2","key":"335_CR6","first-page":"155","volume":"19","author":"A Brouwers","year":"2004","unstructured":"Brouwers A, Verel I, Van Eerd J, Visser G, Steffens M, Oosterwijk E, Corstens F, Oyen W, Van Dongen G, Boerman O. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother Radiopharm. 2004;19(2):155\u201363.","journal-title":"Cancer Biother Radiopharm"},{"issue":"13","key":"335_CR7","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1007\/s00259-024-06827-2","volume":"51","author":"SD Busslinger","year":"2024","unstructured":"Busslinger SD, Mapanao AK, Kegler K, Bernhardt P, Fl\u00fchmann F, Fricke J, Zeevaart JR, K\u00f6ster U, van der Meulen NP, Schibli R, M\u00fcller C. Comparison of the tolerability of 161Tb- and 177Lu-labeled somatostatin analogues in the preclinical setting. Eur J Nucl Med Mol Imaging. 2024;51(13):4049\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"335_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-024-01802-2","author":"ND Calvert","year":"2024","unstructured":"Calvert ND, Baxter J, Torrens AA, Thompson J, Kirby A, Walia J, Ntais S, Hemmer E, Berini P, Hibbert B, Ramunno L, Shuhendler AJ. NIR-II scattering gold superclusters for intravascular optical coherence tomography molecular imaging. Nat Nanotechnol. 2024. https:\/\/doi.org\/10.1038\/s41565-024-01802-2.","journal-title":"Nat Nanotechnol"},{"key":"335_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-07029-6","author":"R Chen","year":"2024","unstructured":"Chen R, Yang X, Li L, Zhao H, Huang G, Liu J. Distinguishing benign from malignant lesions with high [68Ga]Ga-FAPI-04 uptake in oncology patients: insights from dynamic total-body [68Ga]Ga-FAPI-04 PET\/CT. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-07029-6. Online ahead of print.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"335_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-07009-w","author":"A Chirindel","year":"2024","unstructured":"Chirindel A, Nicolas GP, Westerbergh F, McDougall L, Schmid DE, Geistlich S, Tschan VJ, Busslinger SD, Fokkema A, Aceto N, Bernhardt P, van der Meulen NP, Mueller C, Wild D, Schibli R. First-in-human administration of [161Tb]Tb-SibuDAB and comparative dosimetry with standard [177Lu]Lu-PSMA-I&T as part of the PROGNOSTICS phase Ia study. Eur J Nucl Med Mol Imaging. 2024. https:\/\/doi.org\/10.1007\/s00259-024-07009-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"335_CR11","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.7150\/thno.20094","volume":"7","author":"F Cleeren","year":"2017","unstructured":"Cleeren F, Lecina J, Ahamed M, Raes G, Devoogdt N, Caveliers V, McQuade P, Rubins DJ, Li W, Verbruggen A, Xavier C, Bormans G. Al18F-Labeling of Heat-Sensitive biomolecules for positron emission tomography imaging. Theranostics. 2017;7(11):2924\u201339.","journal-title":"Theranostics"},{"issue":"10","key":"335_CR12","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1038\/s41596-018-0040-7","volume":"13","author":"F Cleeren","year":"2018","unstructured":"Cleeren F, Lecina J, Bridoux J, Devoogdt N, Tshibangu T, Xavier C, Bormans G. Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method. Nat Protoc. 2018;13(10):2330\u201347.","journal-title":"Nat Protoc"},{"issue":"1","key":"335_CR14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40658-024-00696-2","volume":"11","author":"L De Nardo","year":"2024","unstructured":"De Nardo L, Santi S, Dalla Piet\u00e0 A, Ferro-Flores G, Azor\u00edn-Vega E, Nascimbene E, Barbieri V, Zorz A, Rosato A, Mel\u00e9ndez-Alafort L. Comparison of the dosimetry and cell survival effect of 177Lu and 161Tb-somatostatin analog radiopharmaceuticals in cancer cell clusters and micrometastases. EJNMMI Phys. 2024;11(1):94.","journal-title":"EJNMMI Phys"},{"key":"335_CR13","doi-asserted-by":"publisher","first-page":"14077","DOI":"10.1021\/acs.jmedchem.4c00924","volume":"67","author":"S Deiser","year":"2024","unstructured":"Deiser S, Fenzl S, K\u00f6nig V, Drexler M, Smith LM, George ME, Beck R, Witney TH, Inoue S, Casini A. (SiFA)SeFe: A hydrophilic Silicon-Based fluoride acceptor enabling versatile peptidic radiohybrid tracers. J Med Chem. 2024;67:14077\u201394.","journal-title":"J Med Chem"},{"issue":"9","key":"335_CR15","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1021\/acs.molpharmaceut.3c00360","volume":"20","author":"M Ducharme","year":"2023","unstructured":"Ducharme M, Hall L, Eckenroad W, Cingoranelli SJ, Houson HA, Jaskowski L, Hunter C, Larimer BM, Lapi SE. Evaluation of [89Zr]Zr-DFO-2Rs15d nanobody for imaging of HER2-positive breast cancer. Mol Pharm. 2023;20(9):4629\u201339.","journal-title":"Mol Pharm"},{"key":"335_CR16","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.1039\/D2CS00889K","volume":"52","author":"Q Fu","year":"2023","unstructured":"Fu Q, Shen S, Sun P, Gu Z, Bai Y, Wang X, Liu Z. Bioorthogonal chemistry for prodrug activation in vivo. Chem Soc Rev. 2023;52:7737\u201372.","journal-title":"Chem Soc Rev"},{"issue":"1","key":"335_CR17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s41181-024-00297-5","volume":"9","author":"LG G\u00e9","year":"2024","unstructured":"G\u00e9 LG, M\u00f8ller MS, Chen C, Cend\u00e0n Castillo V, Langkjaer N, McKee V, Hygum Dam J, McKenzie CJ, Thisgaard H. Exploring a tristhione scorpionate ligand as a suitable chelator for the theranostic pair antimony-119 and antimony-117. EJNMMI Radiopharm Chem. 2024;9(1):75.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"335_CR18","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1021\/acscentsci.4c01369","volume":"10","author":"Z Guo","year":"2024","unstructured":"Guo Z, Wang X, Han Y, Shen S, Tian P, Hu Y, Ding Z, Fu Q, Liu Z. Targeted radionuclide therapy activates prodrugs for treating metastasis. ACS Cent Sci. 2024;10:2321\u201330.","journal-title":"ACS Cent Sci"},{"key":"335_CR19","doi-asserted-by":"crossref","unstructured":"Hindi\u00e9 E, Larouze A, Alcocer-\u00c1vila M, Morgat C, Champion C. Palladium-103 (103Pd\/103mRh), a promising Auger electron emitter for targeted radionuclide therapy of disseminated tumour cells\u2013 absorbed doses in single cells and clusters, with comparison to 177Lu and 161Tb. Theranostics. 2024;14(11):4318\u20134330.","DOI":"10.7150\/thno.95436"},{"key":"335_CR20","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.3390\/ph15121467","volume":"15","author":"N Holzleitner","year":"2022","unstructured":"Holzleitner N, G\u00fcnther T, Beck R, Lapa C, Wester HJ. Introduction of a SiFA moiety into the D-Glutamate chain of DOTA-PP-F11N results in Radiohybrid-Based CCK-2R-Targeted compounds with improved pharmacokinetics in vivo. Pharmaceuticals (Basel). 2022;15:1467.","journal-title":"Pharmaceuticals (Basel)"},{"key":"335_CR21","doi-asserted-by":"publisher","first-page":"1422612","DOI":"10.3389\/frym.2024.1422612","volume":"12","author":"SC Kleinendorst","year":"2024","unstructured":"Kleinendorst SC, Wenker STM, Heskamp S, Rijpkema M, van Lith SAM. Harnessing the power of radiation to battle cancer. Front Young Minds. 2024;12:1422612.","journal-title":"Front Young Minds"},{"key":"335_CR22","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.2967\/jnumed.124.267999","volume":"65","author":"H Koniar","year":"2024","unstructured":"Koniar H, Wharton L, Ingham A, Morales Oliver AP, Merkens H, Rodr\u00edguez-Rodr\u00edguez C, Kunz P, Radchenko V, Yang H, Rahmim A, Uribe C, Schaffer P. Preclinical evaluation of 226Ac as a theranostic agent: imaging, dosimetry, and therapy. J Nucl Med. 2024;65:1762\u20138.","journal-title":"J Nucl Med"},{"issue":"5","key":"335_CR24","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.3390\/cancers12051312","volume":"12","author":"J Lau","year":"2020","unstructured":"Lau J, Rousseau E, Kwon D, Lin KS, Benard F, Chen X. Insight into the development of PET radiopharmaceuticals for oncology. Cancers. 2020;12(5):1312.","journal-title":"Cancers"},{"key":"335_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s41181-024-00304-9","volume":"9","author":"F Lechi","year":"2024","unstructured":"Lechi F, Eriksson J, Odell LR, Wegrzyniak O, Lofblom J, Frejd FY, Zhang B, Eriksson O. Optimized method for fluorine-18 radiolabeling of affibody molecules using RESCA. EJNMMI Radiopharm Chem. 2024;9:73.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"335_CR26","doi-asserted-by":"publisher","first-page":"13975","DOI":"10.1021\/acs.jmedchem.4c00783","volume":"67","author":"K Li","year":"2024","unstructured":"Li K, Tolentino Collado J, Marden JA, Pollard AC, Guo S, Tonge PJ, Qu W. Biological evaluation of D-[18F]Fluoroalanine and D\u2010[18F]Fluoroalanine\u2010d3 as positron emission tomography imaging tracers for bacterial infection. J Med Chem. 2024;67:13975\u2013139.","journal-title":"J Med Chem"},{"issue":"1","key":"335_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s44303-024-00053-z","volume":"2","author":"Y Mori","year":"2024","unstructured":"Mori Y, Novruzov E, Schmitt D, Cardinale J, Watabe T, Choyke PL, Alavi A, Haberkorn U, Giesel F. Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET). Npj Imaging. 2024;2(1):48.","journal-title":"Npj Imaging"},{"key":"335_CR27","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1007\/s00259-023-06316-y","volume":"50","author":"C M\u00fcller","year":"2023","unstructured":"M\u00fcller C, van der Meulen NP, Schibli R. Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics. Eur J Nucl Med Mol Imaging. 2023;50:3181\u20134.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8043","key":"335_CR28","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41586-024-08271-6","volume":"636","author":"EA Newcombe","year":"2024","unstructured":"Newcombe EA, Due AD, Sottini A, Elkj\u00e6r S, Theisen FF, Fernandes CB, Staby L, Delaforge E, Bartling CRO, Brakti I, Bugge K, Schuler B, Skriver K, Olsen JG, Kragelund BB. Stereochemistry in the disorder-order continuum of protein interactions. Nature. 2024;636(8043):762\u20138.","journal-title":"Nature"},{"key":"335_CR29","doi-asserted-by":"crossref","unstructured":"Noble R, Noble D. Understanding living systems. Cambridge Univ. Press; 2023.","DOI":"10.1017\/9781009277396"},{"key":"335_CR30","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2967\/jnumed.119.232934","volume":"61","author":"E O\u2019Neill","year":"2020","unstructured":"O\u2019Neill E, Kersemans V, Allen PD, Terry SYA, Baguna Torres J, Mosley M, Smart S, Lee BQ, Falzone N, Vallis KA, Konijnenberg MW, de Jong M, Nonnekens J, Cornelissen B. Imaging DNA damage repair in vivo after 177Lu-DOTATATE therapy. J Nucl Med. 2020;61:743\u201350.","journal-title":"J Nucl Med"},{"key":"335_CR31","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s11307-024-01948-4","volume":"26","author":"JM Omweri","year":"2024","unstructured":"Omweri JM, Saini S, Houson HA, Tekin V, Pyles JM, Parker CC, Lapi SE. Development of 52Mn labeled trastuzumab for extended time point PET imaging of HER2. Mol Imaging Biology. 2024;26:858\u201368.","journal-title":"Mol Imaging Biology"},{"issue":"9","key":"335_CR32","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.2967\/jnumed.124.267474","volume":"65","author":"A Piccardo","year":"2024","unstructured":"Piccardo A, Bottoni G, Puppo C, Massollo M, Ugolini M, Shoushtari Zadeh Naseri M, Melani E, Tomasello L, Boitano M, DeCensi A, Sambucco B, Campodonico F, Altrinetti V, Ennas M, Urru A, Negro CLA, Timossi L, Treglia G, Introini C, Fiz F. Role of 64CuCl2 PET\/CT in detecting and staging Muscle-Invasive bladder cancer: comparison with Contrast-Enhanced CT and 18F-FDG PET\/CT. J Nucl Med. 2024;65(9):1357\u201363.","journal-title":"J Nucl Med"},{"key":"335_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s41181-024-00288-6","volume":"9","author":"F Porto","year":"2024","unstructured":"Porto F, Cisternino S, Cazzola E, Speltri G, Mou L, Boschi A, Marvelli L, Di Domenico G, Pagnoni A, De Dominicis L, Calliari I, Gennari C, Ucelli L, Pupillo G, Gorgoni G, Esposito J, Martini P. Cyclotron production of manganese-52: a promising avenue for multimodal PET\/MRI imaging. EJNMMI Radiopharm Chem. 2024;9:57.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"335_CR34","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.2967\/jnumed.124.267624","volume":"65","author":"S Poty","year":"2024","unstructured":"Poty S, Ordas L, Dekempeneer Y, Ashgar Parach A, Navarro L, Santens F, Dumauthioz N, Bardies M, Lahoutte T, D\u2019Huyvetter M, Pouget J-P. Optimizing the therapeutic index of sdAb-based radiopharmaceuticals using pretargeting. J Nucl Med. 2024;65:1564\u201370.","journal-title":"J Nucl Med"},{"key":"335_CR35","doi-asserted-by":"publisher","first-page":"108949","DOI":"10.1016\/j.nucmedbio.2024.108949","volume":"138\u2013139","author":"J Raitanen","year":"2024","unstructured":"Raitanen J, Palm L, Hacker M, Balber T, Mitterhauser M. The importance of radiochemical purity: cellular binding and internalization of different radiometal chlorides in prostate cancer cells. Nucl Med Biol. 2024;138\u2013139:108949.","journal-title":"Nucl Med Biol"},{"key":"335_CR37","doi-asserted-by":"publisher","first-page":"101463","DOI":"10.1016\/j.xcrm.2024.101463","volume":"5","author":"M Salehjahromi","year":"2024","unstructured":"Salehjahromi M, Karpinets TV, Sujit SJ, Qayati M, Chen P, Aminu M, Saad MB, Bandyopadhyay R, Hong L, Sheshadri A, Lin J, Antonoff MB, Sepesi B, Ostrin EJ, Toumazis I, Huang P, Cheng C, Cascone T, Vokes NI, Behrens C, Siewerdsen JH, Hazle JD, Chang JD, Zhang J, Lu Y, Godoy MCB, Chung C, Jaffray D, Wistuba I, Jack Lee J, Vaporciyan AA, Gibbons DL, Gladish G, Heymach JV, Wu CC, Zhang J, Wu J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: proof of concept. Cell Rep Med. 2024;5:101463.","journal-title":"Cell Rep Med"},{"issue":"6","key":"335_CR38","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1016\/S1470-2045(24)00037-8","volume":"25","author":"AM Scott","year":"2024","unstructured":"Scott AM, Zeglis BM, Lapi SE, Scott PJH, Windhorst AD, Abdel-Wahab M, Giammarile F, Piaez D, Jalilian A, Knoll P, Korde A, Vichare S, Ayati N, Lee ST, Lyashchenko SK, Zhang J, Urbain JL, Lewis JS. Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics. Lancet Oncol. 2024;25(6):e250\u20139.","journal-title":"Lancet Oncol"},{"issue":"10","key":"335_CR36","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/S1470-2045(24)00402-9","volume":"25","author":"B Shuch","year":"2024","unstructured":"Shuch B, Pantuck AJ, Bernhard JC, Morris MA, Master V, Scott AM, van Praet C, Bailly C, \u00d6nal B, Aksoy T, Merkx R, Schuster DM, Lee ST, Pandit-Taskar N, Fan AC, Allman P, Schmidt K, Tauchmanova L, Wheatcroft M, Behrenbruch C, Hayward CRW, Mulders P. [89Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial. Lancet Oncol. 2024;25(10):1277\u201387.","journal-title":"Lancet Oncol"},{"issue":"30","key":"335_CR39","doi-asserted-by":"publisher","first-page":"6433","DOI":"10.1021\/acs.orglett.4c02227","volume":"26","author":"TE Spiller","year":"2024","unstructured":"Spiller TE, Donabauer K, Brooks AF, Witek JA, Bowden GD, Scott PJH, Sanford MS. Room-Temperature photochemical Copper-Mediated fluorination of Aryl Iodides. Org Lett. 2024;26(30):6433\u20137.","journal-title":"Org Lett"},{"key":"335_CR40","unstructured":"Telix Press Release. Telix Files TLX250-CDx (Zircaix\u00ae) BLA for Kidney Cancer Imaging. https:\/\/telixpharma.com\/news-views\/telix-files-tlx250-cdx-zircaix-bla-for-kidney-cancer-imaging\/ Accessed 10 Jan 2025."},{"key":"335_CR41","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-019-04334-3","volume":"46","author":"SYA Terry","year":"2019","unstructured":"Terry SYA, Nonnekens J, Aerts A, Baatout S, De Jong M, Cornelissen B, Pouget J-P. Call to arms: need for radiobiology in molecular radionuclide therapy. Eur J Nucl Med Mol Imaging. 2019;46:1588\u201390.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"335_CR42","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.2967\/jnumed.123.265524","volume":"64","author":"VJ Tschan","year":"2023","unstructured":"Tschan VJ, Busslinger SD, Bernhardt P, Grundler PV, Zeevaart JR, Koster U, van der Meulen NP, Schibli R, Mueller C. Albumin-Binding and conventional PSMA ligands in combination with 161Tb: biodistribution, dosimetry, and preclinical therapy. J Nucl Med. 2023;64:1625\u201331.","journal-title":"J Nucl Med"},{"key":"335_CR43","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3747\/co.23.3191","volume":"23","author":"M Valdes","year":"2016","unstructured":"Valdes M, Nicholas G, Goss GD, Wheatley-Price P. Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy. Curr Oncol. 2016;23:386\u201390.","journal-title":"Curr Oncol"},{"key":"335_CR44","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1016\/j.scib.2024.07.010","volume":"69","author":"C Wang","year":"2024","unstructured":"Wang C, Xu M, Zhang Z, Zeng S, Shen S, Ding Z, Chen J, Cui XY, Liu Z. Locally unlocks prodrugs by radiopharmaceutical in tumour for cancer therapy. Sci Bull. 2024a;69:2745\u201355.","journal-title":"Sci Bull"},{"key":"335_CR45","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06999-x","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zheng M, Zhao J, Wang C, Zhao S, Bian Y, Dai N, Zheng Y, Sang S, Guo L, Huang C, Zhang H, Jiang J, Xu C, Zhao Q, Han J, Xu T, Qin S, Miao L. Human dose-escalation study of PET imaging CD8+ T-cell infiltration in solid malignancies with [68Ga]Ga -NODAGA-SNA006. Eur J Nucl Med Mol Imaging. 2024b. https:\/\/doi.org\/10.1007\/s00259-024-06999-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"335_CR46","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2967\/jnumed.119.234922","volume":"6","author":"A Wurzer","year":"2020","unstructured":"Wurzer A, Di Carlo D, Schmidt A, Beck R, Eiber M, Schwaiger M, Wester HJ. Radiohybrid ligands: A novel tracer concept exemplified by 18F- or 68Ga-Labeled RhPSMA inhibitors. J Nucl Med. 2020;6:735\u201342.","journal-title":"J Nucl Med"},{"key":"335_CR47","doi-asserted-by":"publisher","first-page":"31401","DOI":"10.1021\/acsnano.4c11278","volume":"18","author":"J Zhu","year":"2024","unstructured":"Zhu J, Zhou W, Yao Y, Zhou X, Ma X, Zhang B, Yang Z, Tang B, Zhu H, Li N. Targeted positron emission Tomography-Tracked biomimetic codelivery synergistically amplifies ferroptosis and pyroptosis for inducing lung cancer regression and Anti-PD-L1 immunotherapy efficacy. ACS Nano. 2024;18:31401\u201320.","journal-title":"ACS Nano"}],"updated-by":[{"DOI":"10.1186\/s41181-025-00351-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000}}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00335-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-025-00335-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00335-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:17:00Z","timestamp":1748863020000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-025-00335-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["335"],"URL":"https:\/\/doi.org\/10.1186\/s41181-025-00335-w","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s41181-025-00351-w","URL":"https:\/\/doi.org\/10.1186\/s41181-025-00351-w","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any original studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SS, JD, CD, RM, JP, GC, MAQ, AD, BC, JE, AD, JH, YS, XY, HJ, MRZ, MY, LP, PC, PL, ZC, CH, TS, JRZ are part of the Editorial Board of EJNMMI Radiopharmacy and Chemistry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}